Replies to post #106571 on Biotech Values

[DewDiligence]

Re: Low-volume Copaxone

Curiously, AEs were higher for the lower-volume dose (18.1% vs. 12.5%, with more infections seen)…

I raised this point in the prologue of #msg-50939364. Teva’s low-volume Copaxone is not a lock to get FDA approval on the first review cycle, IMHO.